This webinar will provide payer and managed care leaders with a clear, visual map of the precision medicine patient access ecosystem, illuminate the roles and handoffs that drive delays, and define specific payer levers, including equity-focused measures, to reduce friction and accelerate timeline, equitable access.

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient is over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient's ability to function (absenteeism and presenteeism) total over $35B annually.

Therefore, it is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal.

A Science & Innovation Webinar, presented by Abbvie.

Parkinson’s disease is a neurodegenerative disorder characterized by the dysfunction and loss of dopamine-producing neurons in the brain, along with the accumulation of Lewy body pathology. The condition leads to a gradual progression of both motor and non-motor symptoms. Although oral dopaminergic drugs provide symptom control for about 3 to 6 years, their benefits decrease over time, resulting in a narrower therapeutic window and worsening symptoms.

Vyalev (Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion) offers the first 24-hour subcutaneous infusion of levodopa-based treatment, specifically designed to help individuals with advanced Parkinson’s Disease experiencing severe motor fluctuations not adequately managed by other therapies.

Join us for an insightful webinar designed especially for pharmacy students embarking on the journey toward managed care pharmacy residency training.

This interactive session features a distinguished panel of Residency Program Directors, who will share guidance on finding the "right fit" program and offer practical strategies for successful engagement throughout the application and interview process. From understanding what programs seek in candidates to tips for making a positive impression, panelists will illuminate both the challenges and opportunities that residency applicants encounter. Attendees will have ample time to ask questions and gain clarity, ensuring a well-equipped plan to navigate each step of the residency pursuit.

Speakers:

Thomas C. Pomfret, PharmD, MPH, BCPS
PGY1 Managed Care Residency Program Director | ForHealth Consulting at UMass Can Medical School

Amanda Bain, PharmD, MPH, MBA
PGY1 Managed Care Residency Program Director | The Ohio State University Health Plan

Spenser Smith, PharmD
PGY1 Managed Care Residency Program Director | BlueCross BlueShield of North Carolina

Ellen M. Feeney, PharmD, BCPS
PGY1 Managed Care Pharmacy Residency Program Director | Highmark Inc.

An AMCP Webinar, hosted by FormularyDecisions®.

Significant policy changes under the new presidential administration are set to impact various healthcare sectors. Upstream influences demand a strategic reevaluation of global supply chains and competitive positioning, while downstream effects will reshape how organizations and communities engage with and serve local populations.

This session will examine the evolving policy landscape and its implications for stakeholders in managed care pharmacy and the biopharmaceutical industry. Through expert insights and dynamic discussion, attendees will gain a practical framework to navigate emerging challenges and opportunities, empowering informed decision-making in a rapidly changing healthcare environment.

A Science & Innovation Webinar, presented by Neurotech.

By the end of this session, attendees will be able to:

• Recognize the significant unmet medical need in the Macular Telangiectasia Type 2 (MacTel), including clinical characteristics, disease progression and implications of delayed or absent treatment.
• Understand the patient journey where patients often navigate through subtle, inconsistent symptoms that affect their activities of daily living and quality of life prior to obtaining a definitive diagnosis.
• Explain the mechanism of action, clinical efficacy, safety profile, and long-term durability of ENCELTO, emphasizing the cell-based gene therapy's ability to address the underlying pathophysiology of MacTel.
• Assess key factors impacting patient access to ENCELTO and potential solutions to balance affordability concerns with appropriate access to treatment.

CMS launched the Medicare Transaction Facilitator Data Module (MTF DM) on June 9, 2025 and has been working with dispensing entities across the U.S. to enroll and onboard since. The CMS MTF Team is continuing our commitment to make sure all dispensing entities have the information and support needed to complete enrollment in the MTF DM to ensure they are prepared for the effectuation of the new negotiated maximum fair prices (MFPs) for selected drugs covered under Medicare Part D beginning on January 1, 2026. Now is the time to enroll in the MTF DM to ensure your pharmacy is ready for January.  The information you provide during the enrollment process is necessary to process MFP refund payments from drug manufacturers. 

Chronic Lymphocytic Leukemia (CLL) is a complex, indolent blood cancer in which immature lymphocytes are found mostly in the blood and bone marrow. It is the most common type of leukemia in adults, affecting an estimated 226,432 people in the United States as of 2022. The entry of Bruton’s tyrosine kinase inhibitors (BTKis) into the treatment landscape caused a shift to more targeted oral therapy. The cost of treatment and medically managing CLL patients within the US healthcare system is of particular interest for healthcare decision makers. The objective of this webinar is to explore the results of a cost-effectiveness analyses of covalent BTKis in first-line (1L) or relapsed/refractory (R/R) settings using data from clinical trials and the US Medicare perspective.